TNBC

May 11, 2018

OncoSec, Merck Partner to Test Immunotherapy Combo in Phase 2 Trial for Triple-negative Breast Cancer

News

OncoSec Medical and Merck have joined efforts to conduct a Phase 2 trial evaluating the safety and effectiveness of ImmunoPulse IL-12 in combination with Keytruda (pembrolizumab) for the treatment of ... Read more

October 9, 2017

Synergys Awarded NCI Grant to Develop SYN001 for Triple-negative Breast Cancer

News

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Synergys Biotherapeutics a grant to support the development of its antibody fusion molecule SYN001 for the treatment of triple negative breast cancer ... Read more

June 1, 2017June 1, 2017

Keytruda Shows Meaningful Clinical Benefit When Combined with Standard Therapy for Aggressive Breast Cancer

News

Two independent studies have added new evidence to the benefits of combined therapies with Merck‘s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of aggressive triple-negative breast cancer (TNBC). Adding Keytruda to standard therapies ... Read more

May 30, 2017

PMD-026 Reduces Triple Negative Breast Cancer Growth, Mice Study Shows

News

PMD-026 reduced tumor growth in mice with triple negative breast cancer (TNBC), according to its developer, Phoenix Molecular Designs. The therapy, which targets the RSK family of enzymes associated with cancer ... Read more

April 21, 2017April 21, 2017

CASI Closes Patient Enrollment in Study of ENMD-2076 for Triple-Negative Breast Cancer

News

CASI Pharmaceuticals has closed enrollment in its Phase 2 clinical trial of ENMD-2076 for previously treated locally advanced or metastatic triple-negative breast cancer (TNBC). The 41 American patients it has enrolled so ... Read more

June 22, 2016June 22, 2016

Triple Negative Breast Cancer Novel Immunotherapy Approach Developed

News

ImMAGE Biotherapeutics recently announced that their immunotherapy approach to treat triple negative breast cancer (TNBC) has shown promising results in in vitro studies and is now being tested on animal ... Read more

May 27, 2016May 27, 2016

Innocrin Pharmaceuticals Initiates Phase 2 Study of Seviteronel in Women with Difficult-to-Treat Breast Cancer

News

Innocrin Pharmaceuticals has initiated dosing in a Phase 2 clinical trial in patients with estrogen receptor-positive (ER+) or triple negative breast cancer (TN BCa) to determine the safety, tolerability, pharmacokinetics and activity ... Read more

May 25, 2016May 25, 2016

Levels of Protein, MCJ, May Predict Chemo Resistance and Relapse Risk in Breast Cancer Patients

News

Breast cancer patients with low expression of a specific protein, methylation-controlled J protein (MCJ), may be resistant to chemotherapy treatments and at high risk of relapse, according to a retrospective study ... Read more

April 4, 2016October 18, 2016

Triple-Negative Breast Cancer Drugs are Focus of Partnership Between SRI Biosciences, Stanford Cancer Institute

News

SRI International and Stanford Cancer Institute will collaborate on an innovative new venture to develop investigational drugs to treat triple-negative breast cancer (TNBC). This new research collaboration will look into the potential ... Read more

March 4, 2016May 16, 2016

Triple Negative Breast Cancer Study Tests Way of Monitoring Metastasis Using Blood Samples

News

Cynvenio Biosystems, Inc. recognized the recent Triple Negative Breast Cancer Day by announcing the launch of a clinical trial in women with triple negative breast cancer (TNBC), a breast cancer subtype marked by negative estrogen-, ... Read more